Shenzhen Chipscreen Biosciences Co. Ltd. has submitted an IND application for CS-231295 tablets for the treatment of tumors, and the application has been accepted by the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA).
Poseida Therapeutics Inc. has announced the nomination of a new development candidate under its collaboration with F. Hoffmann-La Roche Ltd., triggering a milestone payment from Roche to Poseida.
Shine Technologies LLC and WARF Therapeutics, a drug discovery program by the Wisconsin Alumni Research Foundation (WARF), have announced promising preclinical research results from collaborative efforts with the advanced radiotheranostics lab at the University of Wisconsin-Madison.
Chimeric antigen receptor (CAR) T-cell therapies (CAR T) have proven effective in several hematological cancers and are advancing across the pipelines of other types of tumors with limited efficacy, such as in the more complex environment of solid tumors.
Genescience Pharmaceuticals Co. Ltd. has identified phosphatidylinositol 3-kinase α (PI3Kα) inhibitors, particularly PI3Kα (H1047R mutant), reported to be useful for the treatment of cancer and PIK3CA-related overgrowth spectrum.
Scientists at Atmosr SAS and Medetia SAS have synthesized adenine derivatives acting as heat shock protein 90 (HSP90) inhibitors reported to be useful for the treatment of cancer, neurodegenerative diseases, infections, myelofibrosis, acute pancreatitis, psoriasis and ROHHAD (rapid-onset obesity, hypothalamic dysfunction, hypoventilation, autonomic dysregulation).
RSS
